# Prevalence of peripheral neuropathy in pre-diabetes: a systematic review

**Authors:** Varo Kirthi, Anugraha Perumbalath, Emily Brown, Sarah Nevitt, Ioannis N Petropoulos, Jamie Burgess, Rebecca Roylance, Daniel J Cuthbertson, Timothy L Jackson, Rayaz A Malik, Uazman Alam

PMC · DOI: 10.1136/bmjdrc-2020-002040 · BMJ Open Diabetes Research & Care · 2021-05-18

## TL;DR

This paper reviews studies to find out how common peripheral neuropathy is in people with pre-diabetes and how diagnostic methods affect the results.

## Contribution

The study systematically reviews and quantifies the prevalence of peripheral neuropathy in pre-diabetic populations using various diagnostic methods.

## Key findings

- Prevalence estimates of peripheral neuropathy in pre-diabetes ranged from 2% to 77%, with most studies reporting ≥10%.
- Higher prevalence was observed with diagnostic methods like plantar thermography and quantitative sensory testing.
- The study highlights significant variability in prevalence due to differences in diagnostic approaches and populations.

## Abstract

There is growing evidence of excess peripheral neuropathy in pre-diabetes. We aimed to determine its prevalence, including the impact of diagnostic methodology on prevalence rates, through a systematic review conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive electronic bibliographic search was performed in MEDLINE, EMBASE, PubMed, Web of Science and the Cochrane Central Register of Controlled Trials from inception to June 1, 2020. Two reviewers independently selected studies, extracted data and assessed risk of bias. An evaluation was undertaken by method of neuropathy assessment. After screening 1784 abstracts and reviewing 84 full-text records, 29 studies (9351 participants) were included. There was a wide range of prevalence estimates (2%–77%, IQR: 6%–34%), but the majority of studies (n=21, 72%) reported a prevalence ≥10%. The three highest prevalence estimates of 77% (95% CI: 54% to 100%), 71% (95% CI: 55% to 88%) and 66% (95% CI: 53% to 78%) were reported using plantar thermography, multimodal quantitative sensory testing and nerve conduction tests, respectively. In general, studies evaluating small nerve fiber parameters yielded a higher prevalence of peripheral neuropathy. Due to a variety of study populations and methods of assessing neuropathy, there was marked heterogeneity in the prevalence estimates. Most studies reported a higher prevalence of peripheral neuropathy in pre-diabetes, primarily of a small nerve fiber origin, than would be expected in the background population. Given the marked rise in pre-diabetes, further consideration of targeting screening in this population is required. Development of risk-stratification tools may facilitate earlier interventions.

## Linked entities

- **Diseases:** pre-diabetes (MONDO:0006920), peripheral neuropathy (MONDO:0003620)

## Full-text entities

- **Genes:** CCDC26 (CCDC26 long non-coding RNA) [NCBI Gene 137196] {aka GLM7, RAM}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, MFN2 (mitofusin 2) [NCBI Gene 9927] {aka CMT2A, CMT2A2, CMT2A2A, CMT2A2B, CPRP1, HMSN6A}
- **Diseases:** diabetic maculopathy (MESH:D008268), CCM (MESH:D003316), foot ulceration (MESH:D016523), Diabetes (MESH:D003920), weight loss (MESH:D015431), continuous (MESH:D014202), nerve fiber abnormalities (MESH:D000071075), peripheral nerve injury (MESH:D059348), diabetic foot (MESH:D017719), polyneuropathy (MESH:D011115), diabetic retinopathy (MESH:D003930), pain (MESH:D010146), microvascular disease (MESH:D017566), MNSI (MESH:D005547), IFG (MESH:D007003), insulin resistance (MESH:D007333), type 2 diabetes (MESH:D003924), inflammatory (MESH:D007249), cardiovascular disease (MESH:D002318), ESC (MESH:D012871), IGT (MESH:D018149), NCS (MESH:C537568), cardiac autonomic neuropathy (MESH:D006331), pre (MESH:D058246), neuropathic deficits (MESH:D009461), hyperglycemia (MESH:D006943), nerve damage (MESH:D000080902), Neuropathic Pain (MESH:D009437), DPN (MESH:D010523), Diabetic Neuropathy (MESH:D003929), Charcot-Marie-Tooth type 2A (MESH:C537988), mechanical hyperalgesia (MESH:D006930), clinical abnormalities (MESH:D013568), Obesity (MESH:D009765), Neuropathy (MESH:D009422),  (MESH:D011236)
- **Chemicals:** free fatty acids (MESH:D005230), glucose (MESH:D005947), triglycerides (MESH:D014280), -Weinstein (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8137250/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC8137250/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC8137250/full.md

---
Source: https://tomesphere.com/paper/PMC8137250